Cargando…

Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease

Previous studies showed a relationship between lipid oxidation biomarkers from plasma samples and Alzheimer’s Disease (AD), constituting a promising diagnostic tool. In this work we analyzed whether these plasma biomarkers could reflect specific brain oxidation in AD. In this work lipid peroxidation...

Descripción completa

Detalles Bibliográficos
Autores principales: Peña-Bautista, Carmen, Baquero, Miguel, López-Nogueroles, Marina, Vento, Máximo, Hervás, David, Cháfer-Pericás, Consuelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278667/
https://www.ncbi.nlm.nih.gov/pubmed/32397687
http://dx.doi.org/10.3390/antiox9050407
_version_ 1783543384163483648
author Peña-Bautista, Carmen
Baquero, Miguel
López-Nogueroles, Marina
Vento, Máximo
Hervás, David
Cháfer-Pericás, Consuelo
author_facet Peña-Bautista, Carmen
Baquero, Miguel
López-Nogueroles, Marina
Vento, Máximo
Hervás, David
Cháfer-Pericás, Consuelo
author_sort Peña-Bautista, Carmen
collection PubMed
description Previous studies showed a relationship between lipid oxidation biomarkers from plasma samples and Alzheimer’s Disease (AD), constituting a promising diagnostic tool. In this work we analyzed whether these plasma biomarkers could reflect specific brain oxidation in AD. In this work lipid peroxidation compounds were determined in plasma and cerebrospinal fluid (CSF) samples from AD and non-AD (including other neurological pathologies) participants, by means of an analytical method based on liquid chromatography coupled with mass spectrometry. Statistical analysis evaluated correlations between biological matrices. The results did not show satisfactory correlations between plasma and CSF samples for any of the studied lipid peroxidation biomarkers (isoprostanes, neuroprostanes, prostaglandines, dihomo-isoprostanes). However, some of the analytes showed correlations with specific CSF biomarkers for AD and with neuropsychological tests (Mini-Mental State Examination (MMSE), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)). In conclusion, lipid peroxidation biomarkers in CSF samples do not reflect their levels in plasma samples, and no significant differences were observed between participant groups. However, some of the analytes could be useful as cognitive decline biomarkers.
format Online
Article
Text
id pubmed-7278667
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72786672020-06-12 Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease Peña-Bautista, Carmen Baquero, Miguel López-Nogueroles, Marina Vento, Máximo Hervás, David Cháfer-Pericás, Consuelo Antioxidants (Basel) Article Previous studies showed a relationship between lipid oxidation biomarkers from plasma samples and Alzheimer’s Disease (AD), constituting a promising diagnostic tool. In this work we analyzed whether these plasma biomarkers could reflect specific brain oxidation in AD. In this work lipid peroxidation compounds were determined in plasma and cerebrospinal fluid (CSF) samples from AD and non-AD (including other neurological pathologies) participants, by means of an analytical method based on liquid chromatography coupled with mass spectrometry. Statistical analysis evaluated correlations between biological matrices. The results did not show satisfactory correlations between plasma and CSF samples for any of the studied lipid peroxidation biomarkers (isoprostanes, neuroprostanes, prostaglandines, dihomo-isoprostanes). However, some of the analytes showed correlations with specific CSF biomarkers for AD and with neuropsychological tests (Mini-Mental State Examination (MMSE), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)). In conclusion, lipid peroxidation biomarkers in CSF samples do not reflect their levels in plasma samples, and no significant differences were observed between participant groups. However, some of the analytes could be useful as cognitive decline biomarkers. MDPI 2020-05-10 /pmc/articles/PMC7278667/ /pubmed/32397687 http://dx.doi.org/10.3390/antiox9050407 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peña-Bautista, Carmen
Baquero, Miguel
López-Nogueroles, Marina
Vento, Máximo
Hervás, David
Cháfer-Pericás, Consuelo
Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease
title Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease
title_full Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease
title_fullStr Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease
title_full_unstemmed Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease
title_short Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer’s Disease
title_sort isoprostanoids levels in cerebrospinal fluid do not reflect alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278667/
https://www.ncbi.nlm.nih.gov/pubmed/32397687
http://dx.doi.org/10.3390/antiox9050407
work_keys_str_mv AT penabautistacarmen isoprostanoidslevelsincerebrospinalfluiddonotreflectalzheimersdisease
AT baqueromiguel isoprostanoidslevelsincerebrospinalfluiddonotreflectalzheimersdisease
AT lopeznoguerolesmarina isoprostanoidslevelsincerebrospinalfluiddonotreflectalzheimersdisease
AT ventomaximo isoprostanoidslevelsincerebrospinalfluiddonotreflectalzheimersdisease
AT hervasdavid isoprostanoidslevelsincerebrospinalfluiddonotreflectalzheimersdisease
AT chaferpericasconsuelo isoprostanoidslevelsincerebrospinalfluiddonotreflectalzheimersdisease